We have embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies. Novartis partnering interests around AI platforms aim to:
- Enable deeper understanding of disease
- Power small and large molecule design
- Increase predictive safety
- Improve trial design
Interested in biomarker and diagnostic technologies that are designed to optimize the efficiency, safety and therapeutic benefit of our drugs. Technologies may include genomic and proteomic testing as well as artificial intelligence driven solutions.
Seeking partners such as NGOs, academic institutions, and companies to expand and accelerate our portfolio of drugs for neglected diseases, including emerging and tropical infectious diseases.